Product

Aethoxysklerol, approved in the UK as a prescription only medicine, is available as a sterile solution for injection (2ml ampoules) in the following strengths1:

  • 5mg/ml (0.5%)
  • 10mg/ml (1.0%)
  • 30mg/ml (3.0%)

Aethoxysklerol is indicated for sclerotherapy of telangiectasias (spider veins), reticular and varicose veins of the lower extremities. Specific strengths are indicated for the different sized veins1

Aethoxysklerol is recommended in the European guidelines for sclerotherapy2 and is registered for use in more than 30 countries worldwide.

Some of the clinical evidence highlights are detailed below:

Aethoxysklerol microsclerotherapy treating spider and reticular veins with the 0.5% and 1.0% strengths resulted in 95% highly effective clearance and 84% patient satisfaction (measures taken 26 weeks after treatment cessation)3.

An extensive study conducted by 98 experienced phlebologists over a 2-year period, assessed Aethoxysklerol (0.5%, 1.0% and 3.0%) in treating spider veins, smaller venules, and varicose veins.

Participants were asked to compare it to their prior experience with sodium tetradecyl sulphate (STS). Aethoxysklerol was considered more effective by 85% and to have a lower frequency of complications by 90%4.

Aethoxysklerol foam sclerotherapy (1.0%) treating small varicose veins and the great saphenous vein produced clinically effective and well-tolerated clearance1,5 and the 1.0% strength was shown to be equally effective to 0.5% STS in treating 3-6mm veins5.

Aethoxysklerol foam sclerotherapy (3.0%) of the great saphenous vein produced elimination of reflux in 96% of patients, 3 weeks after a single treatment. The mean occlusion length of the vein was 38cm6.

Aethoxysklerol is available from Ferndale Pharmaceuticals and selected wholesalers and pharmacies.

References:

  1. Aethoxysklerol Summary of Product Characteristics.
  2. Rabe E, Breu FX, Cavezzi A et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29 (6):338-354.
  3. Rabe E, Schliephake D, Otto J et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomised, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology 2010; 25:124-131.
  4. Conrad P, Malouf GM, Stacey MC et al. The Australian Polidocanol (Aethoxysklerol) Study. Dermatol Surg 1995; 21:334-336.
  5. Rao J, Wildemore JK, Goldman MP et al. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose veins and telangiectatic leg veins. Dermatol Surg 2005; 31:631-635.
  6. Hamel-Desnos C, Ouvry P, Benigni JP et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: A randomised, double-blind trial with 2 year follow up. “The 3/1 Study”. Eur J Vasc Endovasc Surg 2007; 34: 723-729.

Date of Preparation: September 2020. “Aethoxysklerol” is a trademark of Chemische Fabrik Kreussler & Co. GmbH